全球首款CLDN18.2靶向药国内获批上市,热门靶点竞争格局几何

第一财经
01 Jan

12月31日,国家药品监督管理局官网显示,安斯泰来申报的进口新药注射用佐妥昔单抗(商品名:威络益)上市,用于局部晚期不可切除或转移性胃或胃食管交界处(GEJ)腺癌患者的一线治疗。  佐妥昔单抗是一款靶向治疗药物,为安斯泰来自主研发的全球首款CLDN18.2的IgG1单抗。该药物通过特异性结合CLDN18.2,增强免疫系统对肿瘤细胞的识别和攻击,从而抑制肿瘤生长。  佐妥昔单抗于2024年先后在日本...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10